Expand ZLAB Menu
ZLAB MENU

ZLAB Latest Press Releases

-- January 13, 2026 --

Zai Lab Highlights Strategic Priorities and Global Pipeline Progress at 44th Annual J.P. Morgan Healthcare Conference Business Wire 8:00 AM

-- January 6, 2026 --

Zai Lab Announces National Medical Products Administration (NMPA) Approval of AUGTYRO (repotrectinib) for Patients with NTRK-Positive Solid Tumors Business Wire 7:30 AM

-- January 5, 2026 --

Zai Lab to Present at 44th Annual J.P. Morgan Healthcare Conference Business Wire 7:30 AM

-- December 23, 2025 --

Zai Lab Announces Approval of COBENFY (xanomeline and trospium chloride) in China, a First-in-Class Therapy for Schizophrenia Business Wire 7:30 AM

-- December 8, 2025 --

Zai Lab Announces Dosing of First Participant in Global Phase 1/1b study of ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis Business Wire 7:00 AM

-- December 7, 2025 --

Zai Lab Announces Updates to China's National Reimbursement Drug List Business Wire 12:11 AM

-- November 6, 2025 --

Zai Lab Announces Third Quarter 2025 Financial Results and Recent Corporate Updates Business Wire 7:00 AM

-- October 31, 2025 --

Zai Lab Announces Participation in Investor Conferences in November and December 2025 Business Wire 7:30 AM

-- October 24, 2025 --

Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study Business Wire 9:00 AM

-- October 21, 2025 --

The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners PRNewswire 8:05 AM

-- October 15, 2025 --

Zai Lab to Announce Third Quarter 2025 Financial Results and Recent Corporate Updates on November 6, 2025 Business Wire 7:30 AM

-- October 13, 2025 --

Zai Lab Announces Oral Presentation of Updated Data from Global Phase 1 Trial of Zocilurtatug Pelitecan (ZL-1310), a Potential First-in-Class DLL3-Targeted ADC, at 2025 AACR-NCI-EORTC Conference Business Wire 12:02 PM

-- September 6, 2025 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zai Lab Limited - ZLAB Globe Newswire 10:00 AM

-- September 1, 2025 --

Zai Lab Announces Approval of TIVDAK for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong Business Wire 8:00 PM

-- August 28, 2025 --

Zai Lab Announces Participation in Investor Conferences in September 2025 Business Wire 7:30 AM
Market Data Delayed 15 Minutes